Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Tuberculosis01:23

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Diagnostic Course of Sarcoidosis: A Population-Based Study Highlighting Risk Factors for a Delay in Diagnosis.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2026
Same author

Granuloma Drama.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Perioperative approaches to <i>Candida auris</i> colonization in surgical and transplant patients: insights from an EIN Quick Query.

Infection control and hospital epidemiology·2026
Same author

Management of outpatient parenteral antibiotic therapy: a United States-based multi-center survey.

Antimicrobial stewardship & healthcare epidemiology : ASHE·2026
Same author

Projected Increase in HIV Incidence in 11 States if Ryan White Ends: A Simulation Study.

American journal of public health·2026
Same author

Disease burden associated with influenza activity at the population level.

Epidemiology and infection·2026
Same journal

Influenza Vaccines for Persons Who Are Immunocompromised: A Scoping Review of the Literature.

Open forum infectious diseases·2026
Same journal

Mpox Disease Severity Reduced in Intradermally MVA-BN Vaccinated Compared to Unvaccinated Patients in Sweden: A Retrospective 2024-2025 Observational Case-series.

Open forum infectious diseases·2026
Same journal

Persistent Dominance of Serotype 3 in Noninvasive Pneumococcal Disease in Belgium (2022-2025).

Open forum infectious diseases·2026
Same journal

Cryptococcal Meningitis: Comparison of Short- (≤ 1 Week) Versus Longer-duration (> 1 Week) Liposomal Amphotericin B Induction Therapy and Factors Associated With Clinical Outcomes in HIV and Non-HIV Patients.

Open forum infectious diseases·2026
Same journal

Individualized Therapy Guided by Drug Susceptibility Testing for Multidrug-Resistant Tuberculosis.

Open forum infectious diseases·2026
Same journal

mNGS-Identified <i>Mycobacterium porcinum</i> Infection in a Newly Diagnosed Person With HIV Presenting With Recurrent Suppurative Cervical Lymphadenitis.

Open forum infectious diseases·2026
See all related articles

Related Experiment Video

Updated: Jun 30, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Infectious Disease Provider Perspectives on Shorter Tuberculosis Treatment Regimens.

Aliya Moreira1,2, Dana Hassneiah1,2, Susan E Beekmann3

  • 1Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.

Open Forum Infectious Diseases
|June 29, 2026
PubMed
Summary
This summary is machine-generated.

Infectious disease physicians prefer shorter tuberculosis treatment regimens, but newer guideline-recommended options show low uptake. Barriers include concerns about effectiveness and toxicities of new tuberculosis drugs.

Keywords:
BPALM; HPMZBPaLshorter regimenstuberculosistuberculosis treatment

Related Experiment Videos

Last Updated: Jun 30, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Clinical Practice Guidelines

Background:

  • Current guidelines recommend shorter rifamycin-based regimens (≤4 months) for tuberculosis infection.
  • Newer all-oral regimens include 6-month options for drug-resistant tuberculosis (bedaquiline, pretomanid, linezolid [BPaL/BPaL-M]) and a 4-month regimen for drug-susceptible disease (rifapentine, isoniazid, moxifloxacin [HPMZ]).
  • Implementation of these updated tuberculosis treatment regimens often lags behind guideline recommendations.

Purpose of the Study:

  • To assess current tuberculosis treatment practices among infectious disease clinicians.
  • To identify barriers hindering the adoption of newly recommended tuberculosis treatment regimens.

Main Methods:

  • A survey was distributed to 1501 North American adult infectious disease physician members of the IDSA's Emerging Infections Network.
  • Quantitative analysis of survey responses (percentages) and qualitative analysis of open comments were performed.

Main Results:

  • Ninety-three percent of 349 respondents favored ≤4-month tuberculosis treatment regimens.
  • Low adoption rates were observed for HPMZ (1% use, 5% experience) and BPaL/BPaL-M (39% intended use, 40% unsure).
  • Key barriers included concerns regarding treatment toxicities (HPMZ, linezolid), drug interactions, and medication availability.

Conclusions:

  • Infectious disease physicians prioritize shorter tuberculosis treatment durations but exhibit low uptake of newer guideline-recommended regimens.
  • Concerns about effectiveness and treatment toxicities impede the implementation of novel tuberculosis therapies.
  • Optimizing implementation requires enhanced adverse effect management, monitoring, and shared decision-making strategies.